I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| mesothelial cell | 8 studies | 62% ± 25% | |
| hepatocyte | 3 studies | 39% ± 15% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| mesothelial cell | 8 studies | 62% ± 25% | |
| hepatocyte | 3 studies | 39% ± 15% |
Insufficient scRNA-seq data for expression of PRG4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 10663.20 | 226 / 226 | 87% | 66.30 | 352 / 406 |
| lung | 94% | 5063.43 | 545 / 578 | 42% | 10.01 | 482 / 1155 |
| breast | 62% | 2600.88 | 285 / 459 | 55% | 3.93 | 610 / 1118 |
| adipose | 95% | 12959.39 | 1146 / 1204 | 0% | 0 | 0 / 0 |
| pancreas | 2% | 13.91 | 8 / 328 | 74% | 4.72 | 132 / 178 |
| blood vessel | 64% | 3591.06 | 856 / 1335 | 0% | 0 | 0 / 0 |
| skin | 29% | 537.52 | 517 / 1809 | 20% | 4.68 | 95 / 472 |
| muscle | 40% | 990.49 | 319 / 803 | 0% | 0 | 0 / 0 |
| ovary | 16% | 353.44 | 29 / 180 | 23% | 2.12 | 97 / 430 |
| esophagus | 20% | 314.92 | 282 / 1445 | 14% | 0.67 | 26 / 183 |
| stomach | 8% | 227.77 | 29 / 359 | 22% | 0.88 | 62 / 286 |
| heart | 30% | 2519.75 | 254 / 861 | 0% | 0 | 0 / 0 |
| bladder | 19% | 430.05 | 4 / 21 | 10% | 0.36 | 50 / 504 |
| lymph node | 0% | 0 | 0 / 0 | 28% | 0.73 | 8 / 29 |
| thymus | 15% | 215.66 | 101 / 653 | 11% | 0.52 | 65 / 605 |
| adrenal gland | 13% | 346.32 | 34 / 258 | 6% | 1.08 | 14 / 230 |
| intestine | 6% | 85.12 | 59 / 966 | 11% | 1.00 | 57 / 527 |
| tonsil | 0% | 0 | 0 / 0 | 13% | 1.54 | 6 / 45 |
| prostate | 4% | 40.21 | 9 / 245 | 7% | 0.12 | 33 / 502 |
| uterus | 3% | 172.35 | 5 / 170 | 6% | 2.20 | 29 / 459 |
| brain | 1% | 20.82 | 23 / 2642 | 5% | 1.10 | 34 / 705 |
| kidney | 1% | 7.94 | 1 / 89 | 4% | 0.53 | 36 / 901 |
| peripheral blood | 3% | 89.83 | 25 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.04 | 2 / 80 |
| spleen | 2% | 76.68 | 6 / 241 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006955 | Biological process | immune response |
| GO_0016192 | Biological process | vesicle-mediated transport |
| GO_0005615 | Cellular component | extracellular space |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0030247 | Molecular function | polysaccharide binding |
| GO_0030021 | Molecular function | extracellular matrix structural constituent conferring compression resistance |
| GO_0005044 | Molecular function | scavenger receptor activity |
| Gene name | PRG4 |
| Protein name | Proteoglycan 4 (Lubricin) (Megakaryocyte-stimulating factor) (Superficial zone proteoglycan) [Cleaved into: Proteoglycan 4 C-terminal part] Proteoglycan 4 |
| Synonyms | MSF SZP |
| Description | FUNCTION: Plays a role in boundary lubrication within articulating joints. Prevents protein deposition onto cartilage from synovial fluid by controlling adhesion-dependent synovial growth and inhibiting the adhesion of synovial cells to the cartilage surface.; FUNCTION: Isoform F plays a role as a growth factor acting on the primitive cells of both hematopoietic and endothelial cell lineages. |
| Accessions | ENST00000445192.7 [Q92954-1] ENST00000367482.8 ENST00000533951.5 ENST00000367485.4 [Q92954-3] E9PLR3 ENST00000635041.1 [Q92954-6] ENST00000367483.8 [Q92954-2] Q92954 J3KP74 |
